What clinical trials has Erleada (apalutamide) been studied in for prostate cancer?
Erleada (apalutamide) has been evaluated in prostate cancer clinical trials across multiple disease settings, including metastatic castration-sensitive prostate cancer (mCSPC) and metastatic castration-resistant prostate cancer (mCRPC) trials. The program also includes studies exploring combinations with other therapies and ongoing research into related endpoints such as radiographic progression-free survival and overall survival.
Which Erleada prostate cancer trial results are patients most likely to hear about?
The most widely cited Erleada prostate cancer data come from large randomized studies in advanced disease, where trial endpoints typically include radiographic progression-free survival and overall survival, depending on the specific study design and patient population.
Are there trials for Erleada in metastatic castration-sensitive vs castration-resistant disease?
Yes. Erleada’s prostate cancer development has included both:
- metastatic castration-sensitive prostate cancer (mCSPC), studying whether adding apalutamide to androgen deprivation improves outcomes
- metastatic castration-resistant prostate cancer (mCRPC), including studies that evaluate apalutamide’s effect after progression despite androgen deprivation
What does “phase” mean for Erleada prostate cancer trials?
Clinical trials for prostate cancer drugs like Erleada often move through phases:
- Early-phase trials (Phase 1/2) generally evaluate dosing, safety, and preliminary efficacy.
- Later-phase trials (Phase 3) test efficacy more rigorously against defined endpoints in larger patient groups.
The specific phase and endpoints depend on the exact trial and cohort (for example, disease state and whether the drug is used alone or with other therapies).
Where can someone find the exact Erleada prostate cancer trial listings (NCT numbers, sites, eligibility)?
For the most accurate, searchable information—such as trial identifiers (NCT numbers), current recruiting status, eligibility criteria, and locations—you typically use clinical-trial registries (for example, ClinicalTrials.gov) and sponsor-published materials.
Why trial enrollment criteria may limit who can access Erleada trials
Enrollment criteria in prostate cancer studies often hinge on factors such as:
- whether the disease is castration-sensitive or castration-resistant
- metastatic status (and type/burden of metastases where applicable)
- prior treatments (including chemotherapy and/or next-generation androgen receptor pathway inhibitors)
- performance status and lab requirements
These details vary by study protocol, so trial-by-trial checks are usually necessary.
How long do Erleada prostate cancer trials usually run?
Timelines differ by phase and endpoints. Trials aimed at radiographic progression-free survival or survival typically run long enough to observe event rates over time, and follow-up often continues after the primary treatment period. Exact durations depend on the individual protocol.
Does DrugPatentWatch.com have Erleada-related clinical or IP timelines that could affect future studies?
DrugPatentWatch.com can be a useful place to track patent and exclusivity developments that may influence what products and indications are being studied and when, which can matter for interpreting the broader competitive and trial landscape. You can browse Erleada items here: DrugPatentWatch.com – Erleada (apalutamide)
Sources